Laboratory analysis of the antibody-based COVID-19 therapy GlaxoSmithKline <a href="https://www.reuters.com/companies/GSK.L" target="_blank">(GSK.L)</a> (GSK) is developing with U.S. partner Vir <a href="https://www.reuters.com/companies/VIR.O" target="_blankā¦